Liječnički vjesnik, Vol. 133 No. 9-10, 2011.
Pregledni rad
HISTRELIN ACETATE – THE FIRST ONCE YEARLY LHRH AGONIST
Silvio Altarac
Sažetak
Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leuprolide, goserelin, triptorelin, degarelix and buserelin were administered as either intramuscular or subcutaneous depot injections on a 1, 2, 3 or 6 months basis. Histrelin acetate is the first long-acting luteinising hormone-releasing hormone agonist available as a once-yearly subcutaneous implant.
Ključne riječi
Gonadotropin-releasing hormone – analogs and dirivatives, therapeutic use, administration and dosage; Antineoplastic agents, hormonal – therapeutic use, administration and dosage; Prostatic neoplasms – therapeutic use, pathology; Androgen antagonists – therapeutic use; Testosterone – blood, antagonists and inhibitors; Drug implants
Hrčak ID:
171849
URI
Datum izdavanja:
31.10.2011.
Posjeta: 1.200 *